Table 1

Baseline demographic characteristics

GA (n=54)IFNβ1a-sc (n=47)IFNβ1a-im (n=73)IFNβ1b-sc (n=50)Overall (n=224)p Value
Gender, n(%)
 Male17 (31.5)20 (42.6)21 (28.8)20 (40.0)78 (34.8)0.35*
 Female37 (68.5)27 (57.4)52 (71.2)30 (60.0)146 (65.2)
Age (years)
 Mean36.235.836.736.936.40.96†
 SD8.710.410.411.510.2
Groups, n (%)
 ≤36 years27 (50)25 (53.2)36 (49.3)28 (56)116 (51.8)0.89*
 >36 years27 (50)22 (46.8)37 (50.7)22 (44)108 (48.2)
Evolution forms, n (%)
 RRMS54 (100.0)41 (87.2)70 (95.9)41 (82.0)206 (92)0.00‡
 SPMS0 (0.0)5 (10.7)3 (4.1)6 (12.0)14 (6.2)
 PPMS0 (0.0)1 (2.1)0 (0.0)3 (6.0)4 (1.8)
EDSS, n (%) (n=186)§
 0–127 (52.9)13 (43.3)32 (51.6)14 (32.6)86 (46.2)0.17*
 1.5–624 (47.1)17 (56.7)30 (48.4)29 (67.4)100 (53.8)
  • *Pearson’s χ2 test.

  • †One-way ANOVA test.

  • ‡Fisher’s exact test.

  • §EDSS data were unknown for 38 patients.

  • EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; IFNβ 1a-im, intramuscular interferon β1a; IFNβ1a-sc, subcutaneous interferon β1a; IFNβ1b-sc, subcutaneous interferon β1b; PPMS, primary progressive multiple sclerosis; RRMS, relapse-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.